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ADP-ribosylation, the addition of poly-ADP ribose (PAR) onto proteins, is a response signal to cellular challenges, such as excitotoxicity
or oxidative stress. This process is catalyzed by a group of enzymes referred to as poly(ADP-ribose) polymerases (PARPs). Because the
accumulation of proteins with this modification results in cell death, its negative regulation restores cellular homeostasis: a process
mediated by poly-ADP ribose glycohydrolases (PARGs) and ADP-ribosylhydrolase proteins (ARHs). Using linkage analysis and exome
or genome sequencing, we identified recessive inactivating mutations in ADPRHL2 in six families. Affected individuals exhibited a
pediatric-onset neurodegenerative disorder with progressive brain atrophy, developmental regression, and seizures in association
with periods of stress, such as infections. Loss of the Drosophila paralog Parg showed lethality in response to oxidative challenge that
was rescued by human ADPRHL2, suggesting functional conservation. Pharmacological inhibition of PARP also rescued the phenotype,
suggesting the possibility of postnatal treatment for this genetic condition.ADP-ribosylation is a tightly regulated posttranslational
modification of proteins involved in various essential
physiological and pathological processes, including DNA
repair, transcription, telomere function, and apoptosis.1–3
The addition of poly-ADP-ribose (PAR) is mediated by a
group of enzymes, referred to as poly(ADP-ribose) poly-
merases (PARPs), in response to cellular stressors, such as
excitotoxicity or reactive oxygen species. PARylated
proteins can subsequently initiate cellular stress response
pathways. After resolution of the original insult, ADP-
ribose polymers are rapidly removed.4,5 Although PAR
modification can protect the cell from death in the setting
of cellular stress, excessive PAR accumulation or failure to
reverse PAR modification can trigger a cell-death response
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The AmericanHumans have two genes encoding specific PAR-degrad-
ing enzymes: ADPRHL2 (MIM: 610624; Gene ID: 54936)
and PARG (MIM: 603501). Both are capable of hydrolyzing
the glycosidic bond between ADP-ribose moieties and are
ubiquitously expressed.8,9 ADPRH (MIM: 603081) and
putatively ADPRHL1 (MIM: 610620) encode proteins that
can cleave mono-ADP-ribosylated residues and thus are
not functionally redundant with ADPRHL2 and PARG.8
Studies of in situ hybridization have shown high Adprhl2
expression in the developing mouse forebrain and that
its expression remains high in the cerebellum, cortex,
hippocampus, and olfactory bulb in early postnatal ages
and persists into adulthood.10 Parg/ mice die embryoni-
cally as a result of PAR accumulation and cellular
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Figure 1. Pedigrees of Families with
Mutations in ADPRHL2 and Their Clinical
Presentation
(A) Pedigrees of families 1–6 show consan-
guineous unions (double bar) and a total of
16 affected individuals. Slashes represent
deceased individuals. Black shading indi-
cates affected individuals. Gray shading in-
dicates individuals who passed away from
SUDEP; however, no DNA is available.
(B) Panels show midline sagittal MRI for
one affected individual from each of the
six families. White arrows indicate cere-
bellar atrophy, evidenced by widely spaced
cerebellar folia.but Adprhl2/ mouse embryonic fibroblasts (MEFs) engi-
neered to express the catalytic domain of nuclear PARP1
in mitochondria show PAR accumulation, as well as longer
mitochondrial PAR polymers.12,13
Drosophila melanogaster has a single Parg-like gene, and
null flies are lethal in the larval stage; however, when
grown at a permissive temperature, a few can survive.
The surviving flies display PAR accumulation, neuro-
degeneration, reduced locomotion, and premature
death,14 suggesting increased neuronal vulnerability to
PAR accumulation. Although mutations in enzymes
PARG and PARP have not been reported in human disease,
other members of this pathway have been implicated in
human phenotypes.15 For example, mutations in XRCC1
(MIM: 194360), encoding a molecular scaffold protein
involved in complex assembly during the repair of
DNA-strand breaks, lead to PARP-1 overactivation and are
associated with cerebellar ataxia, ocular motor apraxia,
and axonal neuropathy.16
In this study, we show that mutations in ADPRHL2
underlie an age-dependent recessive epilepsy-ataxia syn-
drome initiating with sudden severe seizures in otherwise
healthy individuals followed by progressive loss of mile-
stones, brain atrophy, and death in childhood.We describe
six independent families carrying ADPRHL2 mutations
leading to a nearly identical epilepsy-ataxia syndrome
(Figure 1A). One of the six families (family 2) lacked docu-
mentation of parental consanguinity, and the parents from
this family were from the same small village. The clinical
details of subjects from all included families are shown in
Table 1, and detailed clinical history is narrated in the
Supplemental Note. The emerging clinical picture is
one of a stress-induced neurodegenerative disease of vari-432 The American Journal of Human Genetics 103, 431–439, September 6, 2018able progression with developmental
delay, intellectual disability, mild
cerebellar atrophy (Figure 1B), and
recurring seizures.
Genome-wide linkage analysis of
14 members of family 1 mapped the
disease locus to an 11 Mb locus in
chromosomal region 1p36 with a
genome-wide-significant multipointLOD score of 3.4 (Figure S1A). Exome sequencing of
individual II-IV-6 at >303 read depth for 96.9% of the
exome revealed a single rare (allele frequency < 1:1,000)
potentially deleterious variant within the linkage interval:
a frameshift ADPRHL2 mutation that segregated with the
phenotype according to a recessive mode of inheritance.
Using GeneMatcher, this international collaborative
group of authors identified further pathogenic alleles in
ADPRHL2.17 After obtaining informed consent from all
participating individuals in accordance with the ethical
standards of the responsible committee on human experi-
mentation at the University of California, San Diego, we
identified a total of six distinct mutations in ADP-ribosyl-
hydrolase-like 2 (ADPRHL2 [Gene ID: 54936]) in the six
families by whole-exome or genome sequencing (see Sup-
plemental Data). All variants were prioritized by allele
frequency, conservation, blocks of homozygosity, and
predicted effect on protein function (see Supplemental
Data), and in all families the homozygous variant in
ADPRHL2 was the top candidate. Variants were confirmed
by Sanger sequencing and segregated with the phenotype
according to a recessive mode of inheritance. All variants
were predicted to be disease causing by MutationTaster.18
These variants were not encountered in dbGaP, the ExAC
Browser, 1000 Genomes, genomAD, or the Greater Middle
East Variome.
ADPRHL2 contains six coding exons, yielding a single
protein-coding transcript, ADP-ribosylhydrolase 3 (ARH3)
(Figure 2A). The encoded 363 amino acid ARH3 is pre-
dicted to have a mitochondrial localization sequence and
single enzymatic ADP-ribosyl-glycohydrolase domain
(Figure 2B). Family 1 carried the homozygous exon
6 mutation c.1000C>T (GenBank: NM_017825), which
introduces a premature stop codon (p.Gln334Ter) pre-
dicted to truncate the highly conserved last 30 amino acids
of the protein, including part of the ADP-ribosylhydrolase
domain. Family 2 harbored the homozygous exon
3 mutation c.316C>T (GenBank: NM_017825), which
also introduces a premature stop codon (p.Gln106Ter) in
the ADP-ribosylhydrolase domain. Family 3 revealed the
homozygous exon 2 missense mutation c.235A>C
(GenBank: NM_017825), which leads to an amino acid
change (p.Thr97Pro) in a residue that is highly conserved
among vertebrates (Figure S2A). Using a previously
published crystal structure of ARH3, we localized this resi-
due to an a-helical loop within the ADP-ribosylhydrolase
domain and the substrate binding site, which is defined
by the position of two Mg2þ ions located in adjacent
binding sites; thus, the residue is predicted to affect
protein structure and enzymatic activity (Figure S2B).19
Family 4 carried the homozygous 5 bp, exon 3 deletion
c.414_418TGCCC (GenBank: NM_017825), which results
in a frameshift (p.Ala139GlyfsTer5) in the ADP-ribosylhy-
drolase domain. Family 5 carried the homozygous exon
4 missense mutation c.530C>T (GenBank: NM_017825),
which leads to an amino acid change (p.Ser177Leu) that
is also highly conserved among vertebrates. It is localized
in a critical a-helical loop within the ADP-ribosylhydrolase
domain, also suggesting an effect on protein structure and
activity. Family 6 carried the homozygous exon 1 missense
mutation c.100G>A (GenBank: NM_017825), which leads
to an amino acid change (p.Asp34Asn) that is highly
conserved among vertebrates. This change is also localized
in a critical a-helical loop within the ADP-ribosylhydrolase
domain, suggesting a potential impact on protein structure
and activity.
The emerging phenotype of recessive ADPRHL2 muta-
tions is a degenerative pediatric-onset stress-induced
epileptic-ataxia syndrome. Individuals with mutations in
this gene are asymptomatic early after birth but gradually
develop a cyclic pattern of illness-related spontaneous
epileptic seizures or present with a neurodegenerative
course including weakness, ataxia, and loss of milestones
followed by clinical deterioration that ultimately leads to
premature death. Most of the subjects succumbed to
sudden unexpected death in epilepsy (SUDEP) or an
apnoic-attack-like clinical presentation, suggesting a
hyperacute presentation prior to the family’s recognition
of a predisposition. We could not establish an obvious ge-
notype-phenotype correlation given that we show below
that the missense mutation also leads to a severe loss of
function. Thus, the clinical variability in the age of onset
might occur because the genetic background or environ-
mental challenges lead to variable susceptibility to
illness-related cellular stress.
The differential diagnosis for this condition was based
upon the presentation of a recessive condition with recur-
rent exacerbations and predominant features of global
developmental delay, intellectual disability, seizures,
neurogenic changes on electromyography, hearing impair-The Americanment, regression, and mild cerebellar atrophy but not
microcephaly or cataracts. The differential diagnosis in
our families included mitochondrial disorders, spastic
ataxia, and peripheral neuropathy.
To determine the impact of these mutations on protein
folding and binding activity, we generated recombinant
proteins in E.coli and purified them by His-tag affinity
chromatography. Our results showed that the p.Gln334Ter
protein was not evident in the soluble fraction, whereas
the wild-type (WT) was recovered with good purity
(Figure S3A). The p.Thr79Pro protein was expressed and
soluble, although possibly recovered with slightly less
purity than WT ARH3. We studied the deleterious impact
of p.Thr79Pro by using circular dichroism spectroscopy
(Figures S3B and S3C). Compared with the WT, this
mutant exhibited reduced a-helical content and an altered
secondary structure, in agreement with the fact that
p.Thr79Pro occurred within an a-helical domain. Further,
the melting temperature (Tm) of p.Thr79Pro was reduced
by more than 10C, confirming destabilization of the
mutant (Figures S3D–S3F). We also found that in contrast
to WT ARH3, the p.Thr79Pro protein was not stabilized
by ligands such as adenosine diphosphate ribose (ADPr)
(Figures S3G–S3I). We confirmed the specificity of this
assay by using adenosine triphosphate (ATP) and ribose-
5-phosphate as negative controls, which were not
predicted to bind or stabilize ARH3. Together, these data
suggest that both disease-causing, truncating mutants
and amino acid substitutions should be destabilized
when expressed in cells.
Because the c.1000C>T (p.Gln334ter) mutation of
family 1 was in the last exon, we first excluded nonsense-
mediated decay (NMD) of the mutant mRNA.We collected
skin biopsies from the father (III-II) and two affected indi-
viduals (II-IV-6 and II-IV-7), generated primary fibroblasts,
and then performed RT-PCR by using primers designed to
amplify the last three exons of ADPRHL2 (Figure S1B).
The father’s and affected individuals’ cells revealed a
band of the expected size and of similar intensity to that
of a healthy control individual, arguing against NMD.
However, when we used an antibody recognizing amino
acids 231–245, lysates derived from the affected individ-
uals showed no detectable ARH3 (Figure 2C; Supplemental
Data), consistent with a null effect of the truncating
mutation. Further, western blot analysis of individual II-2
from family 2 showed an absence of the protein, as pre-
dicted by the early stop codon. Fibroblasts from individual
II-1 from family 3 showed a severely reduced amount of
ARH3 (Figure 2C), consistent with the thermal instability
of this mutant protein (Figures S3D–S3F) and the severe
alteration of its secondary structure (Figures S3B and S3C).
Whereas humans have two known genes with specific
PARG activity (PARG and ADPRHL2; Figure 3A), Drosophila
have a single gene that regulates this process: Parg. Using
the Gal4-UAS system to drive RNAi expression, we found
that Parg knockdown led to a 60% decrease in total Parg
mRNA for flies with the ubiquitous da promoter and aJournal of Human Genetics 103, 431–439, September 6, 2018 433
Table 1. Mutations in ADPRHL2 Cause Various Phenotypes, Including Developmental Delay, Cerebellar Atrophy, Ataxia, and Epilepsy
Family 1
I-IV-1 I-IV-2 I-IV-3 I-IV-5 I-IV-11 II-IV-2 II-IV-5 II-IV-6 (A1)
Gender M F M M M F F M
Country
of origin
UAE UAE UAE UAE UAE UAE UAE UAE
Parental
consanguinity
þ þ þ þ þ þ þ þ
Current age
or age of death
died at 4 years died at 2 years died at 7 years died at 15 years 4 years died at 2 years died at 2 years died at 9 years
Circumstances
of death
in sleep in sleep seizure respiratory
failure
– in sleep
1 week after
flu-like illness
seizure
after playing
respiratory
failure
after long
airplane trip
Mutation
Genomic
(hg19a)
g.36558895C>T g.36558895C>T g.36558895C>T g.36558895C>T g.36558895C>T g.36558895C>T g.36558895C>T g.36558895C>T
cDNA c.1000C>T c.1000C>T c.1000C>T c.1000C>T c.1000C>T c.1000C>T c.1000C>T c.1000C>T
Protein p.Gln334* p.Gln334* p.Gln334* p.Gln334* p.Gln334* p.Gln334* p.Gln334* p.Gln334*
Homozygosity þ þ þ þ þ þ þ þ
Perinatal History
Normal birth þ þ þ þ þ þ þ þ
Normal early
development
þ þ þ þ þ þ þ þ
Psychomotor Development
Speech
development
spoke in
sentences
but then
deteriorated
few words at
2 years
normal until
2.5 years
but then
no further
development
normal until
3.5 years but
then
deteriorated
speaks only
a few words
normal speech
until death
normal speech
until death
normal until
25 years
but then
deteriorated
Motor
development
normal but then
deteriorated
normal until
death
normal
but then
deteriorated
normal but
then
deteriorated
normal but
then
deteriorated
normal but
then
deteriorated
normal until
death
normal
but then
deteriorated
by 2 years
Seizures
Seizure onset 18 months 19 months 19 months 24 months 15 months 24 months 15 months 18 months
Seizure types GTCS GTCS GTCS GTCS absence, GTCS GTCS GTCS absence, GTCS
Neurological Examination
Intellect normal but then
delayed
normal until
death
normal but
then delayed
normal but
then delayed
normal but
then delayed
normal
until death
normal
until death
normal but
then delayed
EEG – – – – – – – generalized
epileptiform
activity, slow
background
MRI (age
performed)
– – – normal (5 years) – – – mild cerebellar
atrophy
(7 years)
(Continued on next page)
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Family 2 Family 3 Family 4 Family 5 Family 6
II-IV-7 (A2) II-2 II-1 II-1 II-3 IV-1 IV-2 II-3
F M F F F M F F
UAE Italy Turkey Pakistan Pakistan Iran Iran Turkey
þ same village þ þ þ þ þ þ
3 years 16 years 15 years 13 years 2 years died at 6 years 3 years 10 years
– – – – – in sleep – –
g.36558895C>T g.36557226C>T g.36556868A>C g.36557324_
36557328delTGCCC
g.36557324_
36557328delTGCCC
g.36557524C>T g.36557524C>T g.36554605G>A
c.1000C>T c.316C>T c.235A>C c.414_418delTGCCC c.414_418delTGCCC c.530C>T c.530C>T c.100G>A
p.Gln334* p.Gln106* p.Thr79Pro p.Ala139Glyfs*4 p.Ala139Glyfs*4 p.Ser177Leu p.Ser177Leu p.Asp34Asn
þ þ þ þ þ þ þ þ
þ þ þ þ þ þ þ þ
þ þ þ þ mild developmental
delay
þ þ þ
normal speech
but then
deteriorated
slow speech normal normal delayed normal until
1.5 years
but then
deteriorated
with difficulty
speaking
speaks only
a few words
delayed
walked normally
at 14 months
but then had
ataxia and poor
balance at
19 months
normal but
then deteriorated
by 2 years
normal normal but then
deteriorated by
2 years
mildly delayed normal until
1 year
but then
deteriorated
normal
but then
deteriorated
by 1.5 years
normal
16 months – – – 9 months 24 months 36 months –
absence, GTCS – – GTCS with illness GTCS with illness multifocal,
GTCS
multifocal,
GTCS
–
normal but
then delayed
normal but
then started
deteriorating
at age 11 yeras
normal mild ID (IQ 60) mild global
developmental
delay
normal but
then stagnated
normal but
then stagnated
mild ID
generalized
epileptiform
activity, slow
background
– – mild slowing
background
activity (3 years)
normal generalized
epileptiform
activity, slow
background
normal normal
mild cerebellar
atrophy (7 years)
cerebellar
vermis atrophy
(11 years)
mild cerebellar
atrophy,
spinal cord
atrophy
(12 years)
mild cerebellar
atrophy (4 years)
normal
(11 months)
– normal
(3 years)
mild cerebellar
vermis atrophy,
spinal cord
atrophy
(15 years)
(Continued on next page)
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Table 1. Continued
Family 1
I-IV-1 I-IV-2 I-IV-3 I-IV-5 I-IV-11 II-IV-2 II-IV-5 II-IV-6 (A1)
EMG or
biopsy
– – – – – – – nerve biopsy
with severe
axonal loss
Onset of
unsteady gait
– – 2.5 years 3 years 2.5 years – – 2.5 years
Other Clinical Features
Exacerbated by
illness and/or
stress
þ þ þ þ þ þ þ þ
Other clinical
features
– – – hypotonia with
repeated
pneumonia,
ventilator
dependent at
time of death
can walk but
is very
unsteady
progressive
weakness
progressive
weakness
repeated
pneumonia,
repeated
cardiac arrest,
profound type II
muscle fiber
atrophy
Clinical presentation for affected subjects from families 1–6. Abbreviations are as follows: þ, yes; –, not available; DTR, deep-tendon reflex; EEG, electroenceph-
alography; EMG, electromyography; F, female; GTCS, generalized tonic-clonic seizure; ID, intellectual disability; M, male; MRI, magnetic resonance imaging; and
SNHL, sensorineural hearing loss.
aUCSC Genome Browser.50% decrease with the neuron-specific promoter, elav
(embryonic lethal abnormal visual system) (Figure S4A).
Whereas the da-Gal4 and PargRNAi lines showed normal
survival, crossing the two together led to daughterless
(da)-mediated expression of PargRNAi, which reduced sur-
vival substantially (Figure S4B). Ubiquitous knockdown
of Parg also led to decreased survival when animals were
exposed to stress with either hydrogen peroxide (H2O2)
in their water or environmental hypoxia (2% O2) (Figures
S4C and S4D). Furthermore, knockdown of Parg specif-
ically in neurons largely recapitulated this phenotype by
using the same two environmental stressors (Figures S4E
and S4F). These data provide evidence that stress leads to
premature death in the absence of Parg and that neurons
play an important role in this phenotype.
However, lethality of these flies was not as severe as in
the Parg27.1 line, which carries a p-element insertion that
deletes two-thirds of the open reading frame (nucelotides
34,622–36,079 of GenBank: Z98254),14 suggesting that
PargRNAi is partially inactivating. These mutant flies with
Parg loss of function lack the protein Parg and show
elevated amounts of PAR, especially in nervous tissue.14
Mutant flies die in larval stages, but 25% of the animals
survive when grown at the permissive 29C temperature.
These adult flies display progressive neurodegeneration,
reduced locomotion, and reduced lifespan,14 consistent
with the individuals’ phenotypes in our families. We
confirmed lethality of the Parg27.1 line and found that
forced expression of Drosophila Parg under the ubiquitous
da promoter in the mutant background increased both sur-
vival and motor activity as measured by an established
‘‘climbing index’’ (Figures 3B and 3C).20 Likewise, expres-
sion of the human ADPRHL2 under the same da promoter436 The American Journal of Human Genetics 103, 431–439, Septemshowed a nearly identical degree of rescue of both survival
and locomotor activity (Figures 3B and 3C). These results
suggest that human ADPRHL2 is a functional paralog of
Drosophila Parg.
We next tested whether this phenotypemight be amelio-
rated by inhibition of protein PARylation. We reasoned
that the requirement for dePARylation should be reduced
by the blockage of stress-induced PARylation. Minocycline
displays PARP inhibitory activity with an IC50 of 42 nM
in humans21 and is well tolerated in flies.22 We fed flies
with a range of concentrations from 0 to 1mg/mLminocy-
cline for 24 hr before stress and measured survival rates
96 hr after stress induction. Drug treatment of flies with
ubiquitous knockdown of Parg revealed a dose-dependent
partial rescue of the lethality (Figure S4G). This rescue
was also seen when the drug was given to flies with
neuron-specific knockdown of Parg (Figure S4H), providing
evidence that PARP inhibition can rescue lethality in vivo.
Although we expect that the effect of minocycline on sur-
vival in this assay was due to its effect on PARP, we cannot
exclude off-target or non-specific effects.22
Given that PARP inhibitors are currently in trials for
various types of cancer, it is possible that these drugs could
be tested for clinical effectiveness in this orphan disease,
where they could have a positive effect. Potentially clini-
cally relevant PARP inhibitors include (1) minocycline,
an FDA-approved tetracycline derivative that displays
PARP inhibitory activity; (2) dihydroisoquinoline (DPQ),
a non-FDA-approved potent PARP-1 inhibitor used in
experimental research; and (3) veliparib (ABT: 888), a
potent PARP-1 and PARP-2 inhibitor currently in clinical
trials for the treatment of various type of cancers (IC50 ¼
42, 37, and 4.4 nM, respectively).21,23ber 6, 2018
Family 2 Family 3 Family 4 Family 5 Family 6
II-IV-7 (A2) II-2 II-1 II-1 II-3 IV-1 IV-2 II-3
– – axonal
polyneuropathy
(4 years)
normal muscle
biopsy (4 years)
– normal (4 years) axonal
polyneuropathy
(4 years)
axonal
polyneuropathy
20 months 11 years 4 years 2.5 years not yet 1.5 years 1.5 years 10 years
þ þ þ þ þ þ þ þ
normal hearing
but then
developed severe
SNHL, severe
kyphoscoliosis,
one episode of
cardiac arrest
myopathic
changes on
muscle biopsy
(11 years)
claw hand and
pes cavus
deformities,
scoliosis, SNHL
at 10 years,
tracheotomy,
ventilation
asthma – progressive
weakness,
tremors,
frequent falling
progressive
weakness,
progressive
external
ophthalmoplegia
distal muscle
atrophy, pes
cavus deformity,
toe abnormality,
scoliosis, brisk
DTRs, positive
Babinski reflex,
intentional tremor,
ataxiaThe extent to which ADPRHL2 and PARG functionally
diverge or converge is not well understood, partly because
of a lack of detailed comparative expression analysis and
biochemical function. PARG demonstrates greater specific
activity than ARH3 for removing PAR from proteins,8
and loss of Parg inmice is embryonically lethal.13 Together,
these data suggest that PARG is likely to be the major
contributor to PAR removal in cells that express both genes
under basal conditions. One possibility is that ADPRHL2Family 1
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p.Gln334Ter
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MLS
Ex1 Ex2 Ex3 Ex4 Ex5 Ex6
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Figure 2. Truncating and Missense ADPRHL2 Mutations in Six Inde
(A) Schematic of ADPRHL2 depicts the coding sequence spanning six
the six identified mutations and their coordinates within the cDNA
(B) Schematic of ARH3 depicts themitochondrial localization sequenc
indicate the position and coordinates of the impact of the described
(C)Western blot of fibroblasts from an unrelated control individual (C
and IV-II-7 from family 1 shows the absence of ARH3 in affected fibr
fibroblasts from an unrelated control individual (C) and affected indi
affected individual II-3 from family 2 shows significantly reduced am
The Americanacts as a backup for PARG to remove excessive PARmoieties
under stress conditions. This would be consistent with the
clinical pesentation of individuals with loss of ADPRHL2,
where phenotypes appear to be induced by environmental
stress. Recent studies have shown that ARH3 acts on a
recently discovered form of Ser-ADP ribosylation.24
For example, studies have illustrated an excessive
accumulation of Ser-poly-ADP-ribosylated enzymes in
ADPRHL2/ cell lines and that ARH3 acts mainly onARH3
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mutations.
), the unaffected carrier father (U), and affected individuals IV-II-6
oblasts. a-tubulin was used as the loading control. Western blot of
vidual II-1 from family 3 and the unaffected carrier mother (U) and
ounts of ARH3. a-tubulin was used as the loading control.
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A B
C
Figure 3. Premature Death and Locomo-
tor Defects inDrosophila PargMutants Are
Rescued by Human ADPRHL2
(A) Schematic of a poly-ADP-ribosylated
protein and the location of cleavage.
PARG and ADPRHL2 both remove poly-
ADP-ribose (PAR) from proteins and cleave
the same site. Drosophila melanogaster has
one PAR-removing enzyme, Parg.
(B) Parg27.1 mutant flies (black) show a se-
vere climbing defect, which was rescued
by ubiquitous forced expression of Parg
(red) ormis-expressionofhumanADPRHL2
in two different transgenic lines (green and
blue).
(C) Parg27.1 mutant flies (black) displayed
decreased survival, which was rescued
with ubiquitous forced expression of Parg
(red) and two different transgenic lines
expressing human ADPRHL2 (green and
blue). Data represent the mean 5 SEM of
eight experiments.Ser-ADPr removal.25 This would be consistent with the
phenotype we see in subjects with loss of ARH3, where
phenotypes do not emerge until environmental stress
insults are encountered. Finally, ARH3 contains a mito-
chondrial localization signal, and thus another possibility
is that ARH3 functions as a mitochondrial-specific glyco-
hydrolase that is required after the induction of oxidative
stress.13
PAR signaling has been shown to play a role in a number
of cellular processes—including the regulation of transcrip-
tion, telomere function, mitotic spindle formation, intra-
cellular trafficking, and energy metabolism—in addition
to apoptosis-inducing-factor (AIF)-mediated apoptosis.2,3
Although we hypothesize that the disease mechanism is
through cell death, it is possible that PAR accumulation
could affect other cellular processes before this. Further
work is needed to characterize these effects in the context
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